Gene therapy to improve high-density lipoprotein metabolism and function

Current Pharmaceutical Design

Volumn 16, Issue 13, 2010, Pages 1531-1544

  van Craeyveld, Eline ^a   Gordts, Stephanie ^a   Jacobs, Frank ^a   de Geest, Bart ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Apolipoprotein a i; Atherosclerosis; Gene therapy; Gene transfer; High density lipoproteins; Reverse cholesterol transport

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ADENOVIRUS VECTOR; ANACETRAPIB; APOLIPOPROTEIN A1; ATORVASTATIN; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; DALCETRAPIB; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; MOPERONE; TORCETRAPIB; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; EXPERIMENTAL STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER; HOMEOSTASIS; HUMAN; INNATE IMMUNITY; LIPOPROTEIN METABOLISM; LIVER CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; THERAPY EFFECT; TRANSGENE;

ANIMALS; GENE THERAPY; GENETIC VECTORS; HOMEOSTASIS; HUMANS; LIPOPROTEINS, HDL; TRANSGENES;

EID: 77952507205     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210791050997     Document Type: Article

References (161)

1. Gordon DJ, Rifkind BM. High-density lipoprotein--the clinicalimplications of recent studies. N Engl J Med 1989; 321: 1311-6.
2. Gordon T, Castelli WP, Hjortland MC, Kannel WB, Dawber TR. High density lipoprotein as a protective factor against coronaryheart disease. The Framingham Study. Am J Med 1977; 62: 707-14.
3. Wilson PW, Abbott RD, Castelli WP. High density lipoproteincholesterol and mortality. The Framingham Heart Study.Arteriosclerosis 1988; 8: 737-41.
4. Salonen JT, Epidemiology of high density lipoproteins andatherosclerosis, in Disorders of HDL. Selected proceedings of theinternational symposium held at the Karolinska hospital. 1990, Smith-Gordon and Company Limited 1990; pp. 43-52.
5. Goldbourt U, Medalie JH. High density lipoprotein cholesterol andincidence of coronary heart disease--the Israeli Ischemic HeartDisease Study. Am J Epidemiol 1979; 109: 296-308.
6. Goldbourt U, Yaari S, Medalie JH. Isolated low HDL cholesterolas a risk factor for coronary heart disease mortality. A 21-yearfollow-up of 8000 men. Arterioscler Thromb Vasc Biol 1997; 17:107-13.
7. Gordon DJ, Probstfield JL, Garrison RJ, Neaton JD, Castelli WP, Knoke JD, et al. High-density lipoprotein cholesterol andcardiovascular disease. Four prospective American studies. Circulation 1989; 79: 8-15.
8. Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, et al. Effect of recombinant ApoA-I Milano on coronaryatherosclerosis in patients with acute coronary syndromes: arandomized controlled trial. JAMA 2003; 290: 2292-300.
9. Tardif JC, Gregoire J, L'Allier PL, Ibrahim R, Lesperance J, Heinonen TM, et al. Effects of reconstituted high-densitylipoprotein infusions on coronary atherosclerosis: a randomizedcontrolled trial. JAMA 2007; 297: 1675-82.
10. Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by humanapolipoprotein AI. Nature 1991; 353: 265-7.
11. Duverger N, Kruth H, Emmanuel F, Caillaud JM, Viglietta C, Castro G, et al. Inhibition of atherosclerosis development incholesterol-fed human apolipoprotein A-I-transgenic rabbits. Circulation 1996; 94: 713-7.
12. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AItransgene corrects apolipoprotein E deficiency- inducedatherosclerosis in mice. J Clin Invest 1994; 94: 899-903.
13. Plump AS, Scott CJ, Breslow JL. Human apolipoprotein A-I geneexpression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E- deficient mouse. Proc NatlAcad Sci USA 1994; 91: 9607-11.
14. Nofer JR, Levkau B, Wolinska I, Junker R, Fobker M, vonEckardstein A, et al. Suppression of endothelial cell apoptosis byhigh density lipoproteins(HDL) and HDL-associatedlysosphingolipids. J Biol Chem 2001; 276: 34480-5.
15. Terasaka N, Yu S, Yvan-Charvet L, Wang N, Mzhavia N, Langlois R, et al. ABCG1 and HDL protect against endothelial dysfunctionin mice fed a high-cholesterol diet. J Clin Invest 2008; 118: 3701-13.
16. Seetharam D, Mineo C, Gormley AK, Gibson LL, Vongpatanasin W, Chambliss KL, et al. High-density lipoprotein promotesendothelial cell migration and reendothelialization via scavengerreceptor-B type I. Circ Res 2006; 98: 63-72.
17. Tso C, Martinic G, Fan WH, Rogers C, Rye KA, Barter PJ. High-density lipoproteins enhance progenitor-mediated endotheliumrepair in mice. Arterioscler Thromb Vasc Biol 2006; 26: 1144-9.
18. Feng Y, Van Craeyveld E, Jacobs F, Lievens J, Snoeys J, De Geest B. Wild-type apo A-I and apo A-I(Milano) gene transfer reducenative and transplant arteriosclerosis to a similar extent. J Mol Med(Berlin, Germany) 2009; 87: 287-97.
19. Feng Y, van Eck M, Van Craeyveld E, Jacobs F, Carlier V, Van Linthout S, et al. Critical role of scavenger receptor-BI-expressingbone marrow-derived endothelial progenitor cells in the attenuationof allograft vasculopathy after human apo A-I transfer. Blood 2009;113: 755-64.
20. Feng Y, Jacobs F, Van Craeyveld E, Brunaud C, Snoeys J, Tjwa M, et al. Human ApoA-I transfer attenuates transplant arteriosclerosisvia enhanced incorporation of bone marrow-derived endothelialprogenitor cells. Arterioscler Thromb Vasc Biol 2008; 28: 278-83.
21. Duffy D, Rader DJ. Update on strategies to increase HDL quantityand function. Nat Rev Cardiol 2009; 6: 455-63.
22. Baroukh N, Lopez CE, Saleh MC, Recalde D, Vergnes L, Ostos MA, et al. Expression and secretion of human apolipoprotein A-I inthe heart. FEBS Lett 2004; 557: 39-44.
23. Timmins JM, Lee JY, Boudyguina E, Kluckman KD, Brunham LR, Mulya A, et al. Targeted inactivation of hepatic Abca1 causesprofound hypoalphalipoproteinemia and kidney hypercatabolism ofapoA-I. J Clin Invest 2005; 115: 1333-42.
24. Hennessy LK, Kunitake ST, Kane JP. Apolipoprotein A-I-containing lipoproteins, with or without apolipoprotein A-II, asprogenitors of pre-beta high-density lipoprotein particles. Biochemistry 1993; 32: 5759-65.
25. Huuskonen J, Olkkonen VM, Jauhiainen M, Ehnholm C. Theimpact of phospholipid transfer protein (PLTP) on HDLmetabolism. Atherosclerosis 2001; 155: 269-81.
26. Jonas A. Lecithin cholesterol acyl transferase. Biochim Biophys Acta 2000; 1529: 245-56.
27. Wang N, Lan D, Chen W, Matsuura F, Tall AR. ATP-bindingcassette transporters G1 and G4 mediate cellular cholesterol effluxto high-density lipoproteins. Proc Natl Acad Sci USA 2004; 101:9774-9.
28. Rothblat GH, de la Llera-Moya M, Atger V, Kellner-Weibel G, Williams DL, Phillips MC. Cell cholesterol efflux: integration ofold and new observations provides new insights. J Lipid Res 1999;40: 781-96.
29. Perret B, Mabile L, Martinez L, Terce F, Barbaras R, Collet X. Hepatic lipase: structure/function relationship, synthesis, andregulation. J Lipid Res 2002; 43: 1163-9.
30. Thuahnai ST, Lund-Katz S, Williams DL, Phillips MC. Scavengerreceptor class B, type I-mediated uptake of various lipids into cells.Influence of the nature of the donor particle interaction with the receptor. J Biol Chem 2001; 276: 43801-8.
31. [31] Trigatti B, Covey S, Rizvi A. Scavenger receptor class B type I inhigh-density lipoprotein metabolism, atherosclerosis and heartdisease: lessons from gene-targeted mice. Biochem Soc Trans 2004; 32: 116-20.
32. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, et al. Effects of torcetrapib in patients at high risk forcoronary events. New Engl J Med 2007; 357: 2109-22.
33. Kastelein JJ, van Leuven SI, Burgess L, Evans GW, Kuivenhoven JA, Barter PJ, et al. Effect of torcetrapib on carotid atherosclerosisin familial hypercholesterolemia. New Engl J Med 2007; 356:1620-30.
34. Nissen SE, Tardif JC, Nicholls SJ, Revkin JH, Shear CL, Duggan WT, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. New Engl J Med 2007; 356: 1304-16.
35. Sofat R, Hingorani AD, Smeeth L, Humphries SE, Talmud PJ, Cooper J, et al. Separating the mechanism-based and off-targetactions of cholesteryl ester transfer protein inhibitors with CETPgene polymorphisms. Circulation 2010; 121: 52-62.
36. Joy T, Hegele RA. The end of the road for CETP inhibitors after torcetrapib? Curr Opin Cardiol 2009; 24: 364-71.
37. Vergeer M, Bots ML, van Leuven SI, Basart DC, Sijbrands EJ, Evans GW, et al. Cholesteryl ester transfer protein inhibitortorcetrapib and off-target toxicity: a pooled analysis of the ratingatherosclerotic disease change by imaging with a new CETPinhibitor (RADIANCE) trials. Circulation 2008; 118: 2515-22.
38. Brousseau ME, Kauffman RD, Herderick EE, Demosky SJ, Jr., Evans W, Marcovina S, et al. LCAT modulates atherogenic plasmalipoproteins and the extent of atherosclerosis only in the presenceof normal LDL receptors in transgenic rabbits. Arterioscler Thromb Vasc Biol 2000; 20: 450-8.
39. Hoeg JM, Santamarina-Fojo S, Berard AM, Cornhill JF, Herderick EE, Feldman SH, et al. Overexpression of lecithin:cholesterol acyltransferase in transgenic rabbits prevents diet-inducedatherosclerosis. Proc Natl Acad Sci USA 1996; 93: 11448-53.
40. Berard AM, Foger B, Remaley A, Shamburek R, Vaisman BL, Talley G, et al. High plasma HDL concentrations associated with enhanced atherosclerosis in transgenic mice overexpressinglecithin-cholesteryl acyltransferase. Nat Med 1997; 3: 744-9.
41. Mehlum A, Muri M, Hagve TA, Solberg LA, Prydz H. Miceoverexpressing human lecithin: cholesterol acyltransferase are notprotected against diet-induced atherosclerosis. APMIS 1997; 105:861-8.
42. Mehlum A, Gjernes E, Solberg LA, Hagve TA, Prydz H. Overexpression of human lecithin:cholesterol acyltransferase inmice offers no protection against diet-induced atherosclerosis. APMIS 2000; 108: 336-42.
43. Furbee JW, Jr., Parks JS. Transgenic overexpression of humanlecithin: cholesterol acyltransferase (LCAT) in mice does notincrease aortic cholesterol deposition. Atherosclerosis 2002; 165:89-100.
44. Alam K, Meidell RS, Spady DK. Effect of up-regulating individualsteps in the reverse cholesterol transport pathway on reversecholesterol transport in normolipidemic mice. J Biol Chem 2001;276: 15641-9.
45. Osono Y, Woollett LA, Herz J, Dietschy JM. Role of the lowdensity lipoprotein receptor in the flux of cholesterol through theplasma and across the tissues of the mouse. J Clin Invest 1995; 95:1124-32.
46. Woollett LA, Kearney DM, Spady DK. Diet modification altersplasma HDL cholesterol concentrations but not the transport ofHDL cholesteryl esters to the liver in the hamster. J Lipid Res 1997; 38: 2289-302.
47. Spady DK, Kearney DM, Hobbs HH. Polyunsaturated fatty acidsup-regulate hepatic scavenger receptor B1 (SR-BI) expression andHDL cholesteryl ester uptake in the hamster. J Lipid Res 1999; 40:1384-94.
48. Jolley CD, Woollett LA, Turley SD, Dietschy JM. Centripetalcholesterol flux to the liver is dictated by events in the peripheralorgans and not by the plasma high density lipoprotein orapolipoprotein A-I concentration. J Lipid Res 1998; 39: 2143-9.
49. Zhang Y, Zanotti I, Reilly MP, Glick JM, Rothblat GH, Rader DJ. Overexpression of apolipoprotein A-I promotes reverse transport ofcholesterol from macrophages to feces in vivo. Circulation 2003;108: 661-3.
50. Zhang Y, Da Silva JR, Reilly M, Billheimer JT, Rothblat GH, Rader DJ. Hepatic expression of scavenger receptor class B type I(SR-BI) is a positive regulator of macrophage reverse cholesteroltransport in vivo. J Clin Invest 2005; 115: 2870-4.
51. Greeve J, Altkemper I, Dieterich JH, Greten H, Windler E. Apolipoprotein B mRNA editing in 12 different mammalianspecies: hepatic expression is reflected in low concentrations ofapoB-containing plasma lipoproteins. J Lipid Res 1993; 34: 1367-83.
52. Nagashima M, McLean JW, Lawn RM. Cloning and mRNA tissuedistribution of rabbit cholesteryl ester transfer protein. J Lipid Res 1988; 29: 1643-9.
53. Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993; 34: 1255-74.
54. Shore B, Shore V. Rabbits as a model for the study of hyperlipoproteinemia and atherosclerosis. Adv Exp Med Biol 1976;67: 123-41.
55. Jacobs F, Van Craeyveld E, Feng Y, De Geest B. The diameter of liver sinusoidal fenestrae is not a major determinant of lipoproteinlevels and atherosclerosis in cholesterol-fed rabbits. CardiovascPathol 2009 [Epub ahead of print].
56. Paigen B, Ishida BY, Verstuyft J, Winters RB, Albee D. Atherosclerosis susceptibility differences among progenitors of recombinant inbred strains of mice. Arteriosclerosis 1990; 10: 316-23.
57. Chapman MJ. Animal lipoproteins: chemistry, structure, and comparative aspects. J Lipid Res 1980; 21: 789-853.
58. Warren RJ, Ebert DL, Mitchell A, Barter PJ. Rabbit hepatic lipasec DNA sequence: low activity is associated with low messenger RNA levels. J Lipid Res 1991; 32: 1333-9.
59. Spady DK, Huettinger M, Bilheimer DW, Dietschy JM. Role ofreceptor-independent low density lipoprotein transport in themaintenance of tissue cholesterol balance in the normal and WHHL rabbit. J Lipid Res 1987; 28: 32-41.
60. Meijer GW, Van der Palen JG, De Vries H, Kempen HJ, Van derVoort HA, Van Zutphen LF, et al. Evaluation of the use of serumlathosterol concentration to assess whole-body cholesterolsynthesis in rabbits. J Lipid Res 1992; 33: 281-6.
61. Poorman JA, Buck RA, Smith SA, Overturf ML, Loose-Mitchell DS. Bile acid excretion and cholesterol 7 alpha-hydroxylaseexpression in hypercholesterolemia-resistant rabbits. J Lipid Res 1993; 34: 1675-85.
62. Schwartz CC, VandenBroek JM, Cooper PS. Lipoproteincholesteryl ester production, transfer, and output in vivo in humans.J Lipid Res 2004; 45: 1594-607.
63. Shamburek RD, Pentchev PG, Zech LA, Blanchette-Mackie J, Carstea ED, VandenBroek JM, et al. Intracellular trafficking of thefree cholesterol derived from LDL cholesteryl ester is defective invivo in Niemann-Pick C disease: insights on normal metabolism of HDL and LDL gained from the NP-C mutation. J Lipid Res 1997;38: 2422-35.
64. Rinninger F, Brundert M, Jackle S, Galle PR, Busch C, Izbicki JR, et al. Selective uptake of high-density lipoprotein-associatedcholesteryl esters by human hepatocytes in primary culture. Hepatology 1994; 19: 1100-14.
65. Trigatti B, Rigotti A, Krieger M. The role of the high-densitylipoprotein receptor SR-BI in cholesterol metabolism. Curr OpinLipidol 2000; 11: 123-31.
66. Brousseau ME, Diffenderfer MR, Millar JS, Nartsupha C, Asztalos BF, Welty FK, et al. Effects of cholesteryl ester transfer proteininhibition on high-density lipoprotein subspecies, apolipoproteinA-I metabolism, and fecal sterol excretion. Arterioscler ThrombVasc Biol 2005; 25: 1057-64.
67. Dietschy JM, Turley SD. Control of cholesterol turnover in themouse. J Biol Chem 2002; 277: 3801-4.
68. Goldberg DI, Beltz WF, Pittman RC. Evaluation of pathways for the cellular uptake of high density lipoprotein cholesterol esters in rabbits. J Clin Invest 1991; 87: 331-46.
69. Cimmino G, Chen W, Speidl WS, Giannarelli C, Ibanez B, Fuster V, et al. Safe and sustained overexpression of functionalapolipoprotein A-I/high-density lipoprotein in apolipoprotein A-I-null mice by muscular adeno-associated viral serotype 8 vectorgene transfer. J Cardiovasc Pharmacol 2009; 54: 405-11.
70. Brunetti-Pierri N, Ng P. Progress towards the clinical application ofhelper-dependent adenoviral vectors for liver and lung genetherapy. Curr Opin Mol Ther 2006; 8: 446-54.
71. Vandenberghe LH, Wilson JM. AAV as an immunogen. Curr GeneTher 2007; 7: 325-33.
72. Lam PY, Sia KC, Khong JH, De Geest B, Lim KS, Ho IA, et al. Anefficient and safe herpes simplex virus type 1 amplicon vector for transcriptionally targeted therapy of human hepatocellular carcinomas. Mol Ther 2007; 15: 1129-36.
73. Zaiss AK, Liu Q, Bowen GP, Wong NC, Bartlett JS, Muruve DA.Differential activation of innate immune responses by adenovirusand adeno-associated virus vectors. J Virol 2002; 76: 4580-90.
74. Gao G, Lu Y, Calcedo R, Grant RL, Bell P, Wang L, et al. Biologyof AAV serotype vectors in liver-directed gene transfer to nonhuman primates. Mol Ther 2006; 13: 77-87.
75. Vandenberghe LH, Wilson JM, Gao G. Tailoring the AAV vectorcapsid for gene therapy. Gene Ther 2009; 16: 311-9.
76. Wang L, Calcedo R, Wang H, Bell P, Grant R, Vandenberghe LH, et al. The pleiotropic effects of natural AAV infections on liver-directed gene transfer in macaques. Mol Ther 2010; 18(1): 126-34.
77. Wang L, Wang H, Bell P, McCarter RJ, He J, Calcedo R, et al. Systematic evaluation of AAV vectors for liver directed genetransfer in murine models. Mol Ther 2010; 18(1): 118-25.
78. Kitajima K, Marchadier DH, Burstein H, Rader DJ. Persistent liverexpression of murine apoA-l using vectors based on adeno-associated viral vectors serotypes 5 and 1. Atherosclerosis 2006;186: 65-73.
79. Vaessen SF, Veldman RJ, Comijn EM, Snapper J, Sierts JA, vanden Oever K, et al. AAV gene therapy as a means to increaseapolipoprotein (Apo) A-I and high-density lipoprotein-cholesterollevels: correction of murine ApoA-I deficiency. J Gene Med 2009;11: 697-707.
80. Liu F, Song Y, Liu D. Hydrodynamics-based transfection inanimals by systemic administration of plasmid DNA. Gene Ther 1999; 6: 1258-66.
81. Zhang G, Budker V, Wolff JA. High levels of foreign geneexpression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999; 10: 1735-7.
82. Chen ZY, He CY, Meuse L, Kay MA. Silencing of episomaltransgene expression by plasmid bacterial DNA elements in vivo. Gene Ther 2004; 11: 856-64.
83. Riu E, Grimm D, Huang Z, Kay MA. Increased maintenance andpersistence of transgenes by excision of expression cassettes fromplasmid sequences in vivo. Hum Gene Ther 2005; 16: 558-70.
84. Chen ZY, He CY, Ehrhardt A, Kay MA. Minicircle DNA vectorsdevoid of bacterial DNA result in persistent and high-leveltransgene expression in vivo. Mol Ther 2003; 8: 495-500.
85. Jacobs F, Snoeys J, Feng Y, Van Craeyveld E, Lievens J, Armentano D, et al. Direct comparison of hepatocyte-specificexpression cassettes following adenoviral and nonviralhydrodynamic gene transfer. Gene therapy 2008; 15: 594-603.
86. Van Linthout S, Collen D, De Geest B. Effect of promoters andenhancers on expression, transgene DNA persistence, andhepatotoxicity after adenoviral gene transfer of humanapolipoprotein A-I. Hum Gene Ther 2002; 13: 829-40.
87. Van Linthout S, Lusky M, Collen D, De Geest B. Persistent hepaticexpression of human apo A-I after transfer with a helper-virusindependent adenoviral vector. Gene Ther 2002; 9: 1520-8.
88. De Geest BR, Van Linthout SA, Collen D. Humoral immuneresponse in mice against a circulating antigen induced byadenoviral transfer is strictly dependent on expression in antigen-presenting cells. Blood 2003; 101: 2551-6.
89. Pastore L, Morral N, Zhou H, Garcia R, Parks RJ, Kochanek S, et al. Use of a liver-specific promoter reduces immune response to thetransgene in adenoviral vectors. Hum Gene Ther 1999; 10: 1773-81.
90. De Geest B, Van Linthout S, Collen D. Sustained expression of human apo A-I following adenoviral gene transfer in mice. GeneTher 2001; 8: 121-7.
91. Mingozzi F, Liu YL, Dobrzynski E, Kaufhold A, Liu JH, Wang Y, et al. Induction of immune tolerance to coagulation factor IXantigen by in vivo hepatic gene transfer. J Clin Invest 2003; 111:1347-56.
92. Franco LM, Sun B, Yang X, Bird A, Zhang H, Schneider A, et al. Evasion of immune responses to introduced human acid alpha-glucosidase by liver-restricted expression in glycogen storagedisease type II. Mol Ther 2005; 12: 876-84.
93. Al-Dosari M, Zhang G, Knapp JE, Liu D. Evaluation of viral andmammalian promoters for driving transgene expression in mouseliver. Biochem Biophys Res Commun 2006; 339: 673-8.
94. Guo ZS, Wang LH, Eisensmith RC, Woo SL. Evaluation of promoter strength for hepatic gene expression in vivo followingadenovirus-mediated gene transfer. Gene Ther 1996; 3: 802-10.
95. Kankkonen HM, Vahakangas E, Marr RA, Pakkanen T, Laurema A, Leppanen P, et al. Long-term lowering of plasma cholesterollevels in LDL-receptor-deficient WHHL rabbits by gene therapy. Mol Ther 2004; 9: 548-56.
96. Wang L, Calcedo R, Nichols TC, Bellinger DA, Dillow A, Verma IM, et al. Sustained correction of disease in naive and AAV2-pretreated hemophilia B dogs: AAV2/8-mediated, liver-directedgene therapy. Blood 2005; 105: 3079-86.
97. De Geest B, Van Linthout S, Lox M, Collen D, Holvoet P. Sustained expression of human apolipoprotein A-I after adenoviralgene transfer in C57BL/6 mice: role of apolipoprotein A-Ipromoter, apolipoprotein A-I introns, and human apolipoprotein Eenhancer. Hum Gene Ther 2000; 11: 101-12.
98. Brinster RL, Allen JM, Behringer RR, Gelinas RE, Palmiter RD. Introns increase transcriptional efficiency in transgenic mice. ProcNatl Acad Sci USA 1988; 85: 836-40.
99. Liu K, Sandgren EP, Palmiter RD, Stein A. R at growth hormonegene introns stimulate nucleosome alignment in vitro and intransgenic mice. Proc Natl Acad Sci USA 1995; 92: 7724-8.
100. Miao CH, Ohashi K, Patijn GA, Meuse L, Ye X, Thompson AR, et al. Inclusion of the hepatic locus control region, an intron, and untranslated region increases and stabilizes hepatic factor IX geneexpression in vivo but not in vitro. Mol Ther 2000; 1: 522-32.
101. Palmiter RD, Sandgren EP, Avarbock MR, Allen DD, Brinster RL.Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci USA 1991; 88: 478-82.
102. Agarwal M, Austin TW, Morel F, Chen J, Bohnlein E, Plavec I. Scaffold attachment region-mediated enhancement of retroviralvector expression in primary T cells. J Virol 1998; 72: 3720-8.
103. Auten J, Agarwal M, Chen J, Sutton R, Plavec I. Effect of scaffoldattachment region on transgene expression in retrovirus vector-transduced primary T cells and macrophages. Hum Gene Ther 1999; 10: 1389-99.
104. Dang Q, Auten J, Plavec I. Human beta interferon scaffold attachment region inhibits de novo methylation and confers long-term, copy number-dependent expression to a retroviral vector. JVirol 2000; 74: 2671-8.
105. Miao CH, Thompson AR, Loeb K, Ye X. Long-term andtherapeutic-level hepatic gene expression of human factor IX afternaked plasmid transfer in vivo. Mol Ther 2001; 3: 947-57.
106. Schiedner G, Hertel S, Johnston M, Biermann V, Dries V, Kochanek S. Variables affecting in vivo performance of high-capacity adenovirus vectors. J Virol 2002; 76: 1600-9.
107. De Geest B, Zhao Z, Collen D, Holvoet P. Effects of adenovirus-mediated human apo A-I gene transfer on neointima formationafter endothelial denudation in apo E-deficient mice. Circulation 1997; 96: 4349-56.
108. O'Riordan CR, Lachapelle A, Delgado C, Parkes V, Wadsworth SC, Smith AE, et al. PEGylation of adenovirus with retention ofinfectivity and protection from neutralizing antibody in vitro and invivo. Hum Gene Ther 1999; 10: 1349-58.
109. Croyle MA, Chirmule N, Zhang Y, Wilson JM. PEGylation of E1-deleted adenovirus vectors allows significant gene expression onreadministration to liver. Hum Gene Ther 2002; 13: 1887-900.
110. Croyle MA, Chirmule N, Zhang Y, Wilson JM. Stealthadenoviruses blunt cell-mediated and humoral immune responsesagainst the virus and allow for significant gene expression uponreadministration in the lung. J Virol 2001; 75: 4792-801.
111. De Geest B, Snoeys J, Van Linthout S, Lievens J, Collen D. Elimination of innate immune responses and liver inflammation by PEGylation of adenoviral vectors and methylprednisolone. HumGene Ther 2005; 16: 1439-51.
112. Lieber A, He CY, Meuse L, Schowalter D, Kirillova I, Winther B, et al. The role of Kupffer cell activation and viral gene expressionin early liver toxicity after infusion of recombinant adenovirusvectors. J Virol 1997; 71: 8798-807.
113. Muruve DA, Barnes MJ, Stillman IE, Libermann TA. Adenoviralgene therapy leads to rapid induction of multiple chemokines andacute neutrophil-dependent hepatic injury in vivo. Hum Gene Ther 1999; 10: 965-76.
114. Wolff G, Worgall S, van Rooijen N, Song WR, Harvey BG, CrystalRG. Enhancement of in vivo adenovirus-mediated gene transfer andexpression by prior depletion of tissue macrophages in the targetorgan. J Virol 1997; 71: 624-9.
115. Zhang Y, Chirmule N, Gao GP, Qian R, Croyle M, Joshi B, et al. Acute cytokine response to systemic adenoviral vectors in mice ismediated by dendritic cells and macrophages. Mol Ther 2001; 3:697-707.
116. Schnell MA, Zhang Y, Tazelaar J, Gao GP, Yu QC, Qian R, et al. Activation of innate immunity in nonhuman primates followin gintraportal administration of adenoviral vectors. Mol Ther 2001; 3:708-22.
117. Liu Q, Zaiss AK, Colarusso P, Patel K, Haljan G, Wickham TJ, et al. The role of capsid-endothelial interactions in the innate immuneresponse to adenovirus vectors. Hum Gene Ther 2003; 14: 627-43.
118. Nunes FA, Furth EE, Wilson JM, Raper SE. Gene transfer into theliver of nonhuman primates with E1-deleted recombinantadenoviral vectors: safety of readministration. Hum Gene Ther 1999; 10: 2515-26.
119. Raper SE, Yudkoff M, Chirmule N, Gao GP, Nunes F, Haskal ZJ, et al. A pilot study of in vivo liver-directed gene transfer with anadenoviral vector in partial ornithine transcarbamylase deficiency. Hum Gene Ther 2002; 13: 163-75.
120. Schnell MA, Zhang Y, Tazelaar J, Gao GP, Yu QC, Qian R, et al. Activation of innate immunity in nonhuman primates followingintraportal administration of adenoviral vectors. Mol Ther 2001; 3:708-22.
121. Croyle MA, Le HT, Linse KD, Cerullo V, Toietta G, Beaudet A, et al. PEGylated helper-dependent adenoviral vectors: highly efficientvectors with an enhanced safety profile. Gene Ther 2005; 12: 579-87.
122. Seregin SS, Appledorn DM, McBride AJ, Schuldt NJ, Aldhamen YA, Voss T, et al. Transient pretreatment with glucocorticoidablates innate toxicity of systemically delivered adenoviral vectorswithout reducing efficacy. Mol Ther 2009; 17: 685-96.
123. Jacobs F, Wisse E, De Geest B. The role of liver sinusoidal cells inhepatocyte-directed gene transfer. Am J Pathol 2010; 176: 14-21.
124. Wisse E. An electron microscopic study of the fenestrated endothelial lining of rat liver sinusoids. J Ultrastruct Res 1970; 31:125-50.
125. Wisse E. An ultrastructural characterization of the endothelial cellin the rat liver sinusoid under normal and various experimentalconditions, as a contribution to the distinction between endothelialand Kupffer cells. J Ultrastruct Res 1972; 38: 528-62.
126. Braet F and Wisse E. Structural and functional aspects of liver sinusoidal endothelial cell fenestrae: a review. Comp Hepatol 2002;1: 1.
127. Snoeys J, Mertens G, Lievens J, van Berkel T, Collen D, Biessen EA, et al. Lipid emulsions potently increase transgene expressionin hepatocytes after adenoviral transfer. Mol Ther 2006; 13: 98-107.
128. Kuzmin AI, Finegold MJ, Eisensmith RC. Macrophage depletionincreases the safety, efficacy and persistence of adenovirus-mediated gene transfer in vivo. Gene Ther 1997; 4: 309-16.
129. Schiedner G, Hertel S, Johnston M, Dries V, van Rooijen N, Kochanek S. Selective depletion or blockade of Kupffer cells leadsto enhanced and prolonged hepatic transgene expression usinghigh-capacity adenoviral vectors. Mol Ther 2003; 7: 35-43.
130. Jacobs F, Feng Y, Van Craeyveld E, Lievens J, Snoeys J, De Geest B. Species differences in hepatocyte-directed gene transfer:implications for clinical translation. Curr Gene Ther 2009; 9: 83-90.
131. Wisse E, De Zanger RB, Charels K, Van Der Smissen P, McCuskey RS. The liver sieve: considerations concerning the structure and function of endothelial fenestrae, the sinusoidal walland the space of Disse. Hepatology 1985; 5: 683-92.
132. Snoeys J, Lievens J, Wisse E, Jacobs F, Duimel H, Collen D, et al. Species differences in transgene DNA uptake in hepatocytes afteradenoviral transfer correlate with the size of endothelial fenestrae. Gene Ther 2007; 14: 604-12.
133. Lievens J, Snoeys J, Vekemans K, Van Linthout S, de Zanger R, Collen D, et al. The size of sinusoidal fenestrae is a criticaldeterminant of hepatocyte transduction after adenoviral genetransfer. Gene Ther 2004; 11: 1523-31.
134. Wisse E, Jacobs F, Topal B, Frederik P, De Geest B. The size ofendothelial fenestrae in human liver sinusoids: implications forhepatocyte-directed gene transfer. Gene therapy 2008; 15: 1193-9.
135. Chen H. Comparative observation of the recombinant adeno-associated virus 2 using transmission electron microscopy andatomic force microscopy. Microsc Microanal 2007; 13: 384-9.
136. Szilagyi JF and Berriman J. Herpes simplex virus L particlescontain spherical membrane-enclosed inclusion vesicles. J GenVirol 1994; 75 (Pt 7): 1749-53.
137. Holvoet P, De Geest B, Van Linthout S, Lox M, Danloy S, Raes K, et al. The Arg123-Tyr166 central domain of human ApoAI is critical for lecithin:cholesterolacyl transferase-induced hyperalphalipoproteinemia and HDL remodeling in transgenicmice. Arterioscler Thromb Vasc Biol 2000; 20: 459-66.
138. De Geest B, Stengel D, Landeloos M, Lox M, Le Gat L, Collen D, et al. Effect of overexpression of human apo A-I in C57BL/6 andC57BL/6 apo E-deficient mice on 2 lipoprotein-associatedenzymes, platelet-activatingfactoracetylhydrolaseandparaoxonase. Comparison of adenovirus-mediated human apo A-Igene transfer and human apo A-I transgenesis. Arterioscler ThrombVasc Biol 2000; 20: E68-75.
139. Reardon CA, Kan HY, Cabana V, Blachowicz L, Lukens JR, Wu Q, et al. In vivo studies of HDL assembly and metabolism usingadenovirus-mediated transfer of ApoA-I mutants in ApoA-I-deficient mice. Biochemistry 2001; 40: 13670-80.
140. Chroni A, Liu T, Gorshkova I, Kan HY, Uehara Y, VonEckardstein A, et al. The central helices of ApoA-I can promoteATP-binding cassette transporter A1 (ABCA1)-mediated lipidefflux. Amino acid residues 220-231 of the wild-type ApoA-I arerequired for lipid efflux in vitro and high density lipoproteinformation in vivo. J Biol Chem 2003; 278: 6719-30.
141. Chroni A, Kan HY, Shkodrani A, Liu T, Zannis VI. Deletions ofhelices 2 and 3 of human apoA-I are associated with severedyslipidemia following adenovirus-mediated gene transfer in apoA-I-deficient mice. Biochemistry 2005; 44: 4108-17.
142. Chroni A, Koukos G, Duka A, Zannis VI. The carboxy-terminalregion of apoA-I is required for the ABCA1-dependent formationof alpha-HDL but not prebeta-HDL particles in vivo. Biochemistry 2007; 46: 5697-708.
143. Kopfler WP, Willard M, Betz T, Willard JE, Gerard RD, MeidellRS. Adenovirus-mediated transfer of a gene encoding humanapolipoprotein A-I into normal mice increases circulating high-density lipoprotein cholesterol. Circulation 1994; 90: 1319-27.
144. Tsukamoto K, Hiester KG, Smith P, Usher DC, Glick JM, RaderDJ. Comparison of human apoA-I expression in mouse models ofatherosclerosis after gene transfer using a second generation adenovirus. J Lipid Res 1997; 38: 1869-76.
145. Benoit P, Emmanuel F, Caillaud JM, Bassinet L, Castro G, Gallix P, et al. Somatic gene transfer of human ApoA-I inhibits athero-sclerosis progression in mouse models. Circulation 1999; 99: 105-10.
146. Feng Y, Jacobs F, Van Craeyveld E, Lievens J, Snoeys J, VanLinthout S, et al. The impact of antigen expression in antigen-presenting cells on humoral immune responses against thetransgene product. Gene therapy 2010; 17: 288-93.
147. Tangirala RK, Tsukamoto K, Chun SH, Usher D, Pure E, Rader DJ. Regression of atherosclerosis induced by liver-directed genetransfer of apolipoprotein A-I in mice. Circulation 1999; 100:1816-22.
148. Kawashiri MA, Zhang Y, Pure E, Rader DJ. Combined effects ofcholesterol reduction and apolipoprotein A-I expression on athero-sclerosis in LDL receptor deficient mice. Atherosclerosis 2002;165: 15-22.
149. Belalcazar LM, Merched A, Carr B, Oka K, Chen KH, Pastore L, et al. Long-term stable expression of human apolipoprotein A-Imediated by helper-dependent adenovirus gene transfer inhibitsatherosclerosis progression and remodels atherosclerotic plaques ina mouse model of familial hypercholesterolemia. Circulation 2003;107: 2726-32.
150. Stary HC, Chandler AB, Glagov S, Guyton JR, Insull W, Jr., Rosenfeld ME, et al. A definition of initial, fatty streak, andintermediate lesions of atherosclerosis. A report from theCommittee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation 1994; 89: 2462-78.
151. Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Jr., et al. A definition of advanced types of atheroscleroticlesions and a histological classification of atherosclerosis. A reportfrom the Committee on Vascular Lesions of the Council onArteriosclerosis, American Heart Association. Arterioscler ThrombVasc Biol 1995; 15: 1512-31.
152. Pastore L, Belalcazar LM, Oka K, Cela R, Lee B, Chan L, et al. Helper-dependent adenoviral vector-mediated long-term expressionof human apolipoprotein A-I reduces atherosclerosis in apo E-deficient mice. Gene 2004; 327: 153-60.
153. Van Craeyveld E, Lievens J, Jacobs F, Feng Y, Snoeys J, De Geest B. Apolipoprotein A-I and lecithin:cholesterol acyltransferasetransfer induce cholesterol unloading in complex atheroscleroticlesions. Gene therapy 2009; 16: 757-65.
154. Acton S, Rigotti A, Landschulz KT, Xu S, Hobbs HH, Krieger M. Identification of scavenger receptor SR-BI as a high densitylipoprotein receptor. Science 1996; 271: 518-20.
155. Rigotti A, Miettinen HE, Krieger M. The role of the high-densitylipoprotein receptor SR-BI in the lipid metabolism of endocrineand other tissues. Endocr Rev 2003; 24: 357-87.
156. Van Linthout S, Spillmann F, Riad A, Trimpert C, Lievens J, Meloni M, et al. Human apolipoprotein A-I gene transfer reducesthe development of experimental diabetic cardiomyopathy. Circulation 2008; 117: 1563-73.
157. Van Linthout S, Spillmann F, Lorenz M, Meloni M, Jacobs F, Egorova M, et al. Vascular-protective effects of high-densitylipoprotein include the downregulation of the angiotensin II type 1receptor. Hypertension 2009; 53: 682-7.
158. Linsel-Nitschke P and Tall AR. HDL as a target in the treatment ofatherosclerotic cardiovascular disease. Nat Rev Drug Discov 2005;4: 193-205.
159. Chowdhury EH. Self-assembly of DNA and cell-adhesive proteinsonto pH-sensitive inorganic crystals for precise and efficienttransgene delivery. Curr Pharm Des 2008; 14(22): 2212-28.
160. Kolovou G, Anagnostopoulou K, Mikhailidis DP, Cokkinos DV. Apolipoprotein E knockout models. Curr Pharm Des 2008; 14(4):338-51.
161. Porcellini E, Davis EJ, Chiappelli M, Ianni E, Di Stefano G, Forti P, et al. Elevated plasma levels of alpha-1-anti-chymotrypsin inage-related cognitive decline and Alzheimer's disease: a potentialtherapeutic target. Curr Pharm Des 2008; 14(26): 2659-64.